Healthcare & BiotechNovo Nordisk Exits Internal Parkinson's Unit, Licenses Program to AI Partner Cellular IntelligenceSalvado•Jun 25, 2026
Corporate StrategyNovo Nordisk Exits Cell Therapy, Hands Parkinson's Assets to AI Startup as Pharma Rewires R&DSalvado•Jun 19, 2026
Corporate StrategyNovo Nordisk Outsources Parkinson's R&D to AI Partner as Big Pharma Drops Vertical IntegrationSalvado•Jun 9, 2026
Corporate AcquisitionsEli Lilly Crosses $20B in 2026 Acquisitions, Wagering AI Makes Bought Pipelines Cheaper Than Built OnesSalvado•May 31, 2026
Pharma StrategyNovo Nordisk's 24.9% Rally Validates AI Licensing Over Internal Cell TherapySalvado•May 31, 2026
Corporate Strategy & Business TransformationNovo Nordisk's 25% Stock Surge Validates Pharma's Pivot to AI Platform OutsourcingSalvado•May 18, 2026
Pharma & HealthcareNovo Nordisk's 24.9% Stock Surge Validates Pharma's Pivot From Internal R&D to AI PartnershipsSalvado•May 13, 2026
Strategic PartnershipsNVIDIA Locks In Dual Pharma Deals With Eli Lilly and Thermo Fisher, Making BioNeMo Drug Discovery's Core AI LayerSalvado•May 1, 2026
Corporate StrategyNVIDIA's BioNeMo Platform Secures Eli Lilly and Thermo Fisher as Enterprise AI Revenue ExpandsSalvado•Apr 21, 2026
Healthcare InvestmentAI-Designed Antibody BD200 Outperforms Existing Cancer Drugs as $60M SPAC Targets AI BiotechSalvado•Apr 19, 2026
Corporate Technology InvestmentNVIDIA Partners with Eli Lilly, Thermo Fisher to Anchor AI Drug Discovery InfrastructureSalvado•Apr 17, 2026
Corporate StrategyNVIDIA Locks In Pharma Giants Lilly and Thermo Fisher as Biotech AI Race AcceleratesSalvado•Apr 11, 2026
Corporate StrategyNVIDIA Secures Eli Lilly, Thermo Fisher for BioNeMo Platform in Pharma AI PushSalvado•Apr 11, 2026
Corporate StrategyNVIDIA Partners with Eli Lilly, Thermo Fisher to Drive BioNeMo AI Drug Discovery PlatformSalvado•Apr 10, 2026
Corporate FinanceNVIDIA BioNeMo Platform Powers AI Drug Discovery Push by Eli Lilly, Thermo FisherSalvado•Apr 10, 2026
Biotech InvestmentNVIDIA BioNeMo Platform Secures Lilly and Thermo Fisher as AI Drug Discovery Partnerships AccelerateSalvado•Apr 9, 2026
Corporate FinanceAI Drug Discovery Firms Draw Capital as Clinical Pipelines Near MarketSalvado•Mar 28, 2026
Corporate StrategyNVIDIA Secures Lilly and Thermo Fisher as BioNeMo Platform Anchors AI-Driven Drug Discovery EcosystemSalvado•Mar 26, 2026
Biotech InvestmentBiotech Companies Report Clinical Progress in AI-Assisted Drug Development ProgramsSalvado•Mar 24, 2026
Corporate StrategyNVIDIA BioNeMo Platform Secures Eli Lilly and Thermo Fisher as Strategic Partners in Drug Discovery PushSalvado•Mar 23, 2026
